Breast cancer is the most commonly diagnosed cancer among women and the high survival rate for early stage disease means that breast cancer survivors represent the largest population of cancer survivors worldwide ([@bib2]; [@bib7]; [@bib26]). In 2010, there were estimated to be 570 000 female breast cancer survivors in the UK, and this is projected to reach nearly 1.7 million by 2040 ([@bib19]).

Many women may adjust well after completing initial treatment such as surgery, chemotherapy, radiotherapy and biological treatment for early breast cancer. However, this is not inevitably the case, and women can be at risk from a wide range of long-term physical and psychosocial effects following their diagnosis and treatment ([@bib17]; [@bib13]; [@bib8]; [@bib1]; [@bib10]; [@bib11]; [@bib27]; [@bib4]). In the UK current health policy advocates a shift away from routine follow-up of cancer survivors and a greater emphasis on individualised needs, promotion of recovery, health and well-being ([@bib6]; [@bib23]). Several randomised studies have shown that open access follow-up appointments are a feasible alternative to routine hospital-based follow-up among breast cancer survivors ([@bib9]; [@bib16]). As a result many UK breast units have adopted follow-up services that are patient-led, enabling quick access to clinical teams as needed; instead of routine follow-up hospital appointments. These types of follow-up, such as the Open Access Follow-Up (OAFU) system used at our institution, are based on a principle of supported self-management.

Patients enter the OAFU programme after completion of the hospital-based treatment (surgery, radiotherapy and chemotherapy). They undergo a consultation with an advanced nurse practitioner regarding long-term treatment-related effects, duration of endocrine therapy, education about healthy life styles, breast cancer awareness and symptoms of recurrence. As part of this assessment patients are asked to complete a holistic needs assessment (HNA) using a formalised questionnaire/checklist to evaluate the whole person's needs including physical, emotional, family, practical, spiritual needs ([Supplementary online Material](#sup1){ref-type="supplementary-material"}). This form is sent to all patients by post 2 weeks before the OAFU consultation as part of it and it is required to be completed prior to the consultation. The HNA is an opportunity for the patients to reflect on his/her needs, and then discuss them at the time of the consultation. Holistic needs assessment is a process of gathering and discussing information with the patient in order to develop an understanding of what the person living with and beyond cancer knows, understands and needs. Moreover, holistic needs assessment helps to tailor an individualised care planning and therefore set up early interventions, with onward referral to relevant support services (such as psychological support, physiotherapy or dieticians). A discharge summary, which includes patient's unmet needs and her care planning, is created by the nurse practitioner at the end of the OAFU consultation and sent to the patient's general practitioner.

In order to optimise this service and to adapt it to the needs of our patient population we have conducted a service evaluation to describe the unmet needs of patients as they transition to supported self-management. The primary objective of this study was therefore to estimate the prevalence of unmet needs in breast cancer survivors entering the OAFU programme. As secondary objectives we aimed to describe the nature of the unmet needs, and what factors might identify those patients at highest risk of having unmet needs at completion of hospital-based treatment.

Materials and methods
=====================

The population studied in this analysis were women with a previous diagnosis of early (stages I--III) breast cancer who had completed their initial treatment (surgery, chemotherapy, radiotherapy) and entered into the OAFU programme at the Royal Marsden Hospital (RMH) NHS Foundation Trust from 1 January to 31 December 2015. The catchment area of the RMH corresponds to central and South-West of London. Survivors of breast cancer who were followed up in clinical trials were not qualified to enter into the OAFU programme. Women with ductal carcinoma in situ, i.e., with no invasive cancer, men and women with invasive breast cancer who were lost before the OAFU appointment were excluded from this analysis ([Figure 1](#fig1){ref-type="fig"}).

Patient characteristics, tumour and treatment characteristic were collected from the electronic patient record (EPR). These included: age, menopausal status, race, marital status, working status, comorbidities according to Charlston scale, use of antidepressants, stage, hormone receptor status, human epidermal growth factor receptor 2-status, type of surgery, type of chemotherapy, endocrine therapy, radiotherapy and time from diagnosis to OAFU consultation.

Unmet needs were assessed using the formalised London HNA questionnaire ([@bib14]; [Supplementary online material](#sup1){ref-type="supplementary-material"}), which was sent to all patients 2 weeks before the OAFU consultation. When the HNA had not been completed prior to the consultation, unmet needs were extracted directly from the EPR at the time of consultation.

Statistical analysis was performed using the Stata 14 program. Chi-squared tests were used to compare clinical and social factors between subjects whose unmet needs were captured from EPR or HNA. Univariate logistic regression analysis were performed to assess clinical and social factors associated with having or not unmet needs. Factors analysed included age, menopausal status, married status, working status, living status, comorbidities, use of antidepressant, underwent mastectomy, axillary clearance, chemotherapy, endocrine treatment were coded as a binary variable and time from diagnoses to OAFU as a continuous variable. Multivariate logistic regression analysis were performed to assess independence of any significant (*P*\<0.05) univariate factors.

This study was approved by the Royal Marsden Hospital Committee for Clinical Research as a Service Evaluation (utilising routinely collected data and not requiring written informed consent).

Results
=======

A total of 738 patients entered the OAFU programme in the 12 months studied, and 625 were eligible for this study ([Figure 1](#fig1){ref-type="fig"}). The median age of patients was 59 years old (range: 27--97). The median time from diagnosis to assessment at OAFU was 8.9 months with an interquartile range from 6.3 to 13.6 months ([Table 1](#tbl1){ref-type="table"}).

Unmet needs were identified in 214 (34%) breast cancer survivors from an HNA questionnaire and in 411 (66%) direct from EPR at the time of OAFU consultation (where the HNA had not been completed prior to the consultation). Demographics, tumour and treatment characteristics were not statistically different between the two groups apart from the type of surgery (*P*=0.02) and the time from diagnosis to OAFU consultation (*P*=0.005).

Unmet needs were categorised in three different groups: 0 needs, 1--4 needs, and ⩾5 needs. Over 60% (61%) of the survivors have at least one need and 18% have ⩾5 unmet needs. Consistently higher levels of unmet needs were identified using the HNA as opposed to extraction from EPR ([Table 2](#tbl2){ref-type="table"}). In the light of this observation we conducted a multivariate analysis (incorporating age, menopausal status, social situation, co-morbidities, treatments received and time from diagnosis to OAFU) to evaluate factors associated with completion of an HNA prior to return to OAFU. The two independent factors associated with completing HNA checklist were age 50 years or older and those who entered into the OAFU programme within 12 months of diagnosis (*P*=0.032 and *P*=0.019, respectively).

We classified the unmet needs in five different categories---practical, family, emotional, spiritual and physical needs -- aligned to the HNA checklist questionnaire ([Supplementary Online Material](#sup1){ref-type="supplementary-material"}). Physical and emotional needs were the most frequently reported (55 and 24%, respectively). Practical, family and spiritual needs were reported in less than 10% (6, 5 and 4%, respectively) ([Table 3](#tbl3){ref-type="table"}). Unmet needs were more frequently identified using HNA assessment than extraction from EPR, for example: physical needs: 79 *vs* 43% (*P*\<0.001), emotional needs: 50 *vs* 10% (*P*\<0.001) ([Table 3](#tbl3){ref-type="table"}). The most frequently reported unmet needs are shown in [Figure 2](#fig2){ref-type="fig"}.

We conducted a multivariate analysis to examine which factors might be associated with patients with higher levels of unmet needs ([Table 4](#tbl4){ref-type="table"}). The model used included age, married status, working status, menopausal status, antidepressant use, comorbidities and treatment received. Receipt of endocrine therapy and chemotherapy were the only significant independent factors associated with having ⩾1 unmet needs *vs* no needs ([Table 4](#tbl4){ref-type="table"}).

General recommendations regarding healthy diet, exercise and alcohol consumption were given in 225 survivors (36%). Healthy diet and exercise recommendations were equally given to 30 and 29%, respectively. Alcohol consumption recommendation was only given in 10% of the survivors. In addition, referrals to acupuncture were made in 62 breast cancer survivors (10%), to treat different symptoms, such as hot flushes (9%), fatigue (3%) and pain (3%).

Discussion
==========

It is well-recognised that cancer survivors may experience long-term or late-effects related to the diagnosis and treatment of their cancer ([@bib17]; [@bib13]; [@bib8]; [@bib1]; [@bib10]; [@bib11]; [@bib27]; [@bib4]). The main aim of this study was to determine the prevalence of unmet needs women who had had previous treatment (with curative intent) for early stage breast cancer. The impetus to do this came from the changes in model of care in the UK, which mean that in many breast units these women are not being seen for regular follow-up.

Our results showed that over 60% of the survivors had at least one unmet need, and 18% of patients had at least five unmet needs. Needs were coded in three different categories: 0 needs, 1--4 needs and ⩾5 needs to be consistent with previous studies ([@bib1]). Similar studies assessing unmet needs in survivors found that 40--60% of survivors of all of type of cancer had a least one unmet need ([@bib1]; [@bib11]; [@bib4]; [@bib15]). In a study conducted by Armes *et al*, in 1425 cancer survivors (including 801 with breast cancer) 34% experienced ⩾5 unmet needs ([@bib1]). It is not possible to compare between these studies, as the methods of ascertainment are different; nonetheless, it is clear that a significant proportion of breast cancer survivors have multiple unmet needs. Several studies have also shown that breast cancer survivors reported more unmet needs than other cancer survivors ([@bib11]; [@bib4]). Women who had had previous chemotherapy or endocrine therapy were most likely to report unmet needs, most likely as a result of the attendant toxicities of these treatments.

Physical needs were the most commonly reported followed by emotional needs (55 and 24%, respectively), which is consistent with data published by the American Society of Clinical Oncology (ASCO) and other sources which report that 40% survivors experienced at least one physical need and 29% at least one emotional need ([@bib4]). [@bib12] reported that cancer survivors often reported that their medical needs are met, but psychological needs remain unaddressed. Likewise, in several studies conducted specifically among breast cancer survivors emotional needs such as fear of recurrence and anxiety were the most commonly frequently reported ([@bib1]; [@bib11]).

The two most commonly reported unmet needs were: hot flushes (23%) and fatigue (21%). Hot flushes and other menopausal symptoms are a well-recognised problem in breast cancer survivors ([@bib25]; [@bib22]; [@bib21]). However, it is also well-recognised that a variety of interventions, including behavioural, pharmacological and complementary may ameliorate these symptoms ([@bib20]; [@bib28]). Therefore it is important that proactive management of these symptoms be offered and be available to patients who are no longer being seen in secondary care. Fatigue is an unmet challenge in breast cancer survivors, and the results from this analysis are consistent with data published by Bower *et al* where 25--30% survivors of breast cancer reported cancer-related fatigue ([@bib3]). As for menopausal symptoms, some interventions may help with cancer-related fatigue, and it is important that patients have access to support and advice ([@bib5]). In our study, recommendations regarding exercise and acupuncture to manage cancer-related fatigue were made in 43 (7%) and 16 (3%), respectively. In addition, general recommendations regarding healthy life styles including exercise, healthy diet and alcohol cessation were given in 225 (36%) of breast cancer survivors. Taking into account the impact that healthy life style changes have in cancer survivors, we are aware that more consistent advice and support should be given in the future ([@bib24]).

Unmet needs were more likely to be detected when patients were assessed using the HNA as opposed extraction from EPR. This observation might be explained by the fact that having a formalised checklist that patients can complete at their leisure might lead to higher levels of reporting than in a face-to-face consultation and enable patients to self-reflect on their needs and concerns. In addition, the HNA questionnaire includes spiritual, family and practical needs, such as work and finances, that are not generally assessed by health professionals. This also might be partly explained by the fact that patients having an HNA assessment were more likely to undergo that assessment within 12 months of diagnosis (76 *vs* 65% for EPR extraction, *P*=0.005). Nonetheless all patients undergoing assessment had of course completed their treatment at the time of this assessment, and in univariate analysis of needs *vs* no needs, there was no difference in the proportion of patients reporting needs between those who were assessed at less than 12 months or more than 12 months. The significance of the higher rate of ascertainment with HNA is unknown. However, evidence suggests that the HNA contributes to a better identification of a cancer survivors' needs which helps to tailor an individualised care planning and therefore set up early interventions ([@bib23]). An electronic HNA (eHNA) has also been developed and piloted in four sites in UK. The benefits of this are an increase in the number of HNA completed compared to paper-based HNA, more rapid data processing, audit and analysis and the potential ability to share reproducible outcome data sets across cancer units and centres ([@bib18]).

The main limitation of this study is its retrospective nature. There is a risk of bias with those patients completing HNA potentially being selected for those with more needs. Furthermore, some patients (either by HNA or EPR) may under or over-report symptoms. In addition, we were unable to assess the severity of unmet needs and whether they were present before the diagnosis of breast cancer. In the absence of longitudinal data, it is also not clear from this study, to what extent the needs reported may resolve over time.

Irrespective it is clear that a significant proportion of women with a previous diagnosis of early breast cancer have a number of unmet needs as they move from hospital follow-up to patient-self self-management in an Open Access Follow-up programme. Those women at particular risk are those who have had chemotherapy or are receiving endocrine therapy, as reported in other studies ([@bib1]). It is vitally important, that women coming to the end of their hospital-based routine follow-up have their needs assessed, ideally with a structured tool such as the HNA or eHNA. It is equally important that where unmet needs are found, women are empowered to access help and expertise and resources should be available to help them.
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![**Consort diagram of survivors of BC who entered into the OAFU programme in 2015.**](bjc2017283f1){#fig1}

![**Top ten most frequent unmet needs among 625 survivors of BC (frequency ⩾10%).**](bjc2017283f2){#fig2}

###### Patients' demographics, tumour and treatment characteristics

  **Characteristics**                        **Unmet needs using HNA form** ***n*** **(%)**   **Unmet needs using EPR** ***n*** **(%)**   **Total** ***n*** **(%)**    ***P*****-value**
  ------------------------------------------ ------------------------------------------------ ------------------------------------------- --------------------------- -------------------
  Total breast cancer survivors              214 (34)                                         411 (66)                                    625 (100)                             
  **Patient characteristics**                                                                                                                                         
  Age                                                                                                                                                                           
   Median                                    62                                               58                                          59                                    
   Range                                     30--97                                           27--92                                      27--97                                
   SD                                        12                                               13                                          13                               *P*=0.092
   \<40-year-old                             6 (3)                                            24 (6)                                      30 (5)                                
   ⩾40-year-old                              208 (97)                                         387(94)                                     595 (95)                              
  Menopausal status                                                                                                                                                             
   Premenopausal                             55 (26)                                          123 (30)                                    178 (28)                         *P*=0.267
   Postmenopausal                            159 (74)                                         288 (70)                                    447 (72)                              
  Race                                                                                                                                                                          
   Caucasian                                 191 (89)                                         365 (89)                                    556 (89)                         *P*=0.674
   Asian                                     16 (8)                                           27 (6)                                      43 (7)                                
   Black                                     7 (3)                                            19 (5)                                      26 (4)                                
  Marital status                                                                                                                                                                
   Single                                    16 (8)                                           45 (11)                                     61 (10)                          *P*=0.777
   Married/ with partner                     119 (55)                                         225 (55)                                    344 (55)                              
   Divorced                                  20 (9)                                           40 (10)                                     60 (9)                                
   Widow                                     21(10)                                           29 (7)                                      50 (8)                                
   Not reported                              38 (18)                                          72 (17)                                     110 (18)                              
  Working status                                                                                                                                                                
   Working                                   87 (41)                                          178 (44)                                    265 (42)                         *P*=0.474
   Not working                               95 (44)                                          170 (41)                                    265 (42)                              
   Not reported                              32(15)                                           63 (15)                                     95 (16)                               
  Living with                                                                                                                                                                   
   Alone                                     56 (26)                                          98 (24)                                     154 (25)                         *P*=0.474
   With someone                              137 (64)                                         276 (67)                                    413 (66)                              
   Not reported                              21 (10)                                          37 (9)                                      58 (9)                                
  Comorbidities                                                                                                                                                                 
   Yes                                       29 (14)                                          56 (14)                                     85 (14)                          *P*=0.980
   No                                        185 (86)                                         355 (86)                                    540 (86)                              
  Use of antidepressants                                                                                                                                                        
   Yes                                       13 (6)                                           33 (8)                                      46 (7)                           *P*=0.375
   No                                        201 (94)                                         378 (92)                                    579 (93)                              
  Previous invasive cancer                                                                                                                                                      
   Yes                                       24 (11)                                          47 (11)                                     71 (11)                          *P*=0.934
   No                                        190 (89)                                         364 (89)                                    554 (89)                              
  Time from diagnoses to OAFU                                                                                                                                                   
   \< 12 months                              162 (76)                                         266 (65)                                    428 (68)                         *P*=0.005
   ⩾ 12 months                               52 (24)                                          145 (35)                                    197 (32)                              
   Median time from diagnosis to OAFU        8 months                                         9.5 months                                  8.9 months                       *P*=0.005
  **Tumour and treatment characteristics**                                                                                                                            
  Stage                                                                                                                                                                         
   I                                         80 (37)                                          136 (33)                                    216 (35)                              
   II                                        115 (54)                                         238 (58)                                    353 (56)                         *p*=0.615
   III                                       19 (9)                                           37 (9)                                      56 (9)                                
  Hormone receptor status                                                                                                                                                       
   Positive                                  175 (82)                                         341 (83)                                    516 (83)                         *P*=0.709
   Negative                                  39 (18)                                          70 (17)                                     109 (17)                              
  HER2- status                                                                                                                                                                  
   Positive                                  27 (13)                                          64 (16)                                     91 (15)                          *P*=0.320
   Negative                                  187 (87)                                         347 (84)                                    534 (85)                              
  Surgery                                                                                                                                                                       
   Mastectomy                                53 (25)                                          140 (34)                                    193 (31)                         *P*=0.017
   Wide local excision                       161 (75)                                         271 (66)                                    432 (69)                              
  Axillary clearance                                                                                                                                                            
   Yes                                       41 (19)                                          95 (24)                                     136 (22)                         *P*=0.230
   No (SLNB)                                 172 (80)                                         310 (75)                                    482 (77)                              
   Not done                                  1 (1)                                            6 (1)                                       7(1)                                  
  Chemotherapy                                                                                                                                                                  
   Yes                                       91 (42)                                          170 (41)                                    261 (42)                         *P*=0.780
   No                                        123 (58)                                         241 (59)                                    364 (58)                              
  Taxanes                                                                                                                                                                       
   Yes                                       60 (28)                                          132 (32)                                    192 (31)                         *P*=0.294
   No                                        154 (72)                                         279 (68)                                    433 (69)                              
  Trastuzumab                                                                                                                                                                   
   Yes                                       20 (9)                                           50 (12)                                     70 (11)                          *P*=0.289
   No                                        194 (91)                                         361 (88)                                    555 (89)                              
  Endocrine treatment                                                                                                                                                           
   Yes                                       172 (80)                                         332 (81)                                    504 (81)                         *P*=0.903
   No                                        42 (20)                                          79 (19)                                     121 (19)                              
  Type of endocrine treatment                                                                                                                                                   
   Tamoxifen                                 53 (25)                                          107 (26)                                    160 (26)                         *P*=0.903
   Aromatase inh                             113 (53)                                         212 (51)                                    325 (52)                              
   Goserelin+Tam                             3 (1)                                            11 (3)                                      14 (2)                                
   Goserelin+AI                              3 (1)                                            2 (1)                                       5 (1)                                 
   No hormonal treatment                     42 (20)                                          79 (19)                                     121 (19)                              

Abbreviations: AI=aromatase inhibitors; EPR=Electronic Patient Record; HER2=human epidermal growth factor receptor 2; HNA=Holistic Needs Assessment; OAFU=Open Access Follow-Up; SLNB=sentil lymph node biopsy; Tam=tamoxifen.

###### Frequency of unmet needs evaluated using either HNA or EPR

                    **Unmet needs evaluated using HNA** ***n*** **(%)**   **Unmet needs evaluated using EPR** ***n*** **(%)**   **Total** ***n*** **(%)**  ***P*****-value**
  ---------------- ----------------------------------------------------- ----------------------------------------------------- --------------------------- -------------------
  Total patients                            214                                                   411                                      625              
  No needs                                34 (16)                                              208 (51)                                 242 (39)           *P*\<0.001
  1--4 needs                              72 (34)                                              199 (48)                                 271 (43)            
  ⩾5 needs                               108 (50)                                                4 (1)                                  112 (18)            

Abbreviations: EPR=Electronic Patient Record; HNA=Holistic Needs Assessment.

###### Frequency of specific unmet needs

  **Categories of unmet needs**               **Unmet needs using HNA** ***n*** **(%)**   **Unmet needs using EPR** ***n*** **(%)**   **Total unmet needs** ***n*** **(%)**  ***P*****-value**
  ------------------------------------------ ------------------------------------------- ------------------------------------------- --------------------------------------- -------------------
  Total patients                                                 214                                         411                                       625                    
  Physical                                                    168 (79)                                    175 (43)                                  343 (55)                 *P*\<0.001
   Hot flushes                                                 88 (41)                                     55 (14)                                  143 (23)                 *P*\<0.001
   Fatigue                                                     91 (43)                                     38 (9)                                   129 (21)                 *P*\<0.001
   Pain                                                        62 (29)                                     58 (14)                                  120 (19)                 *P*\<0.001
   Sleep problems                                              74 (35)                                     14 (3)                                    88 (14)                 *P*\<0.001
   Dry, itchy or sore skin                                     52 (24)                                     16 (4)                                    68 (11)                 *P*\<0.001
   Tingling in hands or feet                                   52 (24)                                     18 (4)                                    70 (11)                 *P*\<0.001
   Changes in weight                                           47 (22)                                     14 (3)                                    61 (10)                 *P*\<0.001
   Feeling swollen                                             31 (15)                                     16 (4)                                    47 (8)                  *P*\<0.001
   Other medical condition                                     40 (19)                                      7 (2)                                    47 (8)                  *P*\<0.001
   Moving around or walking                                    42 (20)                                      3 (1)                                    45 (7)                  *P*\<0.001
   Constipation or diarrhoea                                   27 (13)                                      4 (1)                                    31 (5)                  *P*\<0.001
   Cough                                                       30 (14)                                      3 (1)                                    33 (5)                  *P*\<0.001
   Breathless                                                  31 (14)                                      3 (1)                                    34 (5)                  *P*\<0.001
   Wound care                                                  13 (6)                                       9 (2)                                    22 (4)                  *P*\<0.012
   Indigestion                                                 24 (11)                                      2 (1)                                    26 (4)                  *P*\<0.001
   Changes in eating or appetite                               22 (10)                                      1 (1)                                    23 (4)                  *P*\<0.001
   Personal appearance                                         23 (11)                                      2 (1)                                    25 (4)                  *P*\<0.001
   Sore or dry mouth                                           25 (12)                                      1 (1)                                    26 (4)                  *P*\<0.001
   Nauseas or vomiting                                         13 (6)                                       3(1)                                     16 (3)                  *P*\<0.001
   Communication                                               10 (5)                                       0 (0)                                    10 (2)                  *P*\<0.001
   Changes in taste                                            14 (7)                                       1 (1)                                    15 (2)                  *P*\<0.001
   Passing urine                                                8 (4)                                       0 (0)                                     8(1)                   *P*\<0.001
   High temperature                                             5 (2)                                       0 (0)                                     5 (1)                  *P*\<0.002
  Emotional                                                   107 (50)                                     40 (10)                                  147 (24)                 *P*\<0.001
   Worry, fear or anxiety                                      76 (36)                                     24 (6)                                   100 (16)                 *P*\<0.001
   Sadness or depression                                       48 (22)                                     17 (4)                                    65 (10)                 *P*\<0.001
   Memories or concentration problems                          57 (27)                                      4 (1)                                    61 (10)                 *P*\<0.001
   Anger, frustration or guilt                                 39 (18)                                      2 (1)                                    41 (7)                  *P*\<0.001
   Sexual concerns                                             19 (9)                                       5 (1)                                    24 (4)                  *P*\<0.001
   Loneliness or isolation                                     22 (10)                                      1 (1)                                    23 (4)                  *P*=0.001
   Hopeless                                                     7 (3)                                       1 (1)                                     8 (1)                  *P*\<0.001
  Practical                                                    36 (17)                                      1 (1)                                    37 (6)                  *P*\<0.001
   Work or education                                           21 (10)                                      0 (0)                                    21 (3)                  *P*\<0.001
   Making plans                                                20 (9)                                       0 (0)                                    20 (3)                  *P*\<0.001
   Housing or finances                                         16 (8)                                       0 (0)                                    16 (3)                  *P*\<0.001
   Caring responsibilities                                     14 (7)                                       1 (1)                                    15 (2)                  *P*\<0.001
   Laundry or housework                                        11 (5)                                       0 (0)                                    11 (2)                  *P*\<0.001
   Grocery or shopping                                          7 (3)                                       0 (0)                                     7 (1)                  *P*\<0.001
   Information needs                                            9 (4)                                       0 (0)                                     9 (1)                  *P*\<0.001
   Transport and parking                                        6 (3)                                       0 (0)                                     6 (1)                  *P*\<0.001
   Preparing food                                               6 (3)                                       0 (0)                                     6 (1)                  *P*\<0.001
   Bathing and dressing                                         4 (2)                                       0 (0)                                     4 (1)                  *P*\<0.001
  Family                                                       26 (12)                                      5 (1)                                    31 (5)                  *P*\<0.001
   Relation with children                                      14 (7)                                       2 (1)                                    16 (3)                  *P*\<0.001
   Relation with partner                                       11 (5)                                       2 (1)                                    13 (2)                  *P*\<0.001
   Relation with others                                        10 (5)                                       1 (1)                                    11 (2)                  *P*\<0.001
  Spiritual                                                    25 (12)                                      1 (1)                                    26 (4)                  *P*\<0.001
   Loss of meaning or purpose on life                          13 (6)                                       4 (1)                                    17 (3)                  *P*\<0.001
   Regret about the past                                       15 (7)                                       0 (0)                                    15 (2)                  *P*\<0.001
  Loss of faith or other spiritual concern                      3 (1)                                       0 (0)                                     3 (1)                  *P*\<0.001

Abbreviations: EPR=Electronic Patient Record; HNA=Holistic Needs Assessment.

###### Variables associated with ⩾1 unmet needs (univariate and multivariate analyisis)

                                                     **Univariate**   **Multivariate**                               
  --------------------------------- ----- ----- ---- ---------------- ------------------ ------- ------ ------------ ------------
  **Age**                                                                                                            
  \<50                              114   67    59   1.14             0.75--1.72         0.543   NA     NA           NA
  ⩾50                               551   316   62                                                                    
  **Married**                                                                                                        
  N                                 171   100   58   1.13             0.78--1.64         0.532   NA     NA           NA
  Y                                 334   211   61                                                                    
  **Working**                                                                                                        
  N                                 265   151   57   1.33             0.94--1.88         0.110   NA     NA           NA
  Y                                 265   169   64                                                                    
  **Living alone**                                                                                                   
  N                                 413   245   59   1.20             0.82--1.76         0.350   NA     NA           NA
  Y                                 154   98    64                                                                    
  **Comorbidities**                                                                                                  
  N                                 540   330   61   0.95             0.59--1.52         0.827   NA     NA           NA
  Y                                 85    53    62                                                                    
  **Antidepressants**                                                                                                
  N                                 579   350   60   0.60             0.31--1.17         0.134   NA     NA           NA
  Y                                 46    33    72                                                                    
  **Menopause status**                                                                                               
  Pre                               178   115   65   0.82             0.57--1.18         0.282   NA     NA           NA
  Post                              447   268   60                                                                    
  **Mastectomy**                                                                                                     
  N                                 432   257   59   1.28             0.90--1.82         0.170   NA     NA           NA
  Y                                 193   126   65                                                                    
  **Axillary clearance**                                                                                             
  N                                 482   293   61   1.18             0.80--1.76         0.407   NA     NA           NA
  Y                                 136   88    65                                                                    
  **Chemotherapy**                                                                                                   
  N                                 364   205   56   0.60             0.43--0.84         0.003   0.50   0.35--0.71   *P*\<0.001
  Y                                 261   178   68                                                                    
  **Endocrine treatment alone**                                                                                      
  N                                 121   60    50   0.55             0.37--0.82         0.004   0.44   0.29--0.67   *P*\<0.001
  Y                                 504   323   64                                                                    
  **Radiotherapy**                                                                                                   
  N                                 105   61    58   0.85             0.56--1.31         0.463   NA     NA           NA
  Y                                 520   322   62                                                                    
  **Time from diagnosis to OAFU**                                                                                    
  \<12 months                       428   264   62   0.95             0.67--1.34         0.761   NA     NA           NA
  ⩾12 months                        197   119   60                                                                    

Abbreviations: CI=confidence interval; OAFU=Open Access Follow-Up; OR=odds ratio.
